Boston Scientific Lifts 2025 Guidance Following Strong Q2 Performance
Jul 24,2025
Boston Scientific (NYSE: BSX) has raised its full-year outlook for both revenue and earnings after posting second-quarter results that exceeded market expectations.
For the quarter ending June 30, 2025, the Massachusetts-based medical device company reported revenue of $5.06 billion, representing a 22.8% year-over-year increase. Net income rose sharply to $797 million (54 cents per share), more than doubling from $324 million a year earlier. Adjusted earnings per share (EPS), excluding non-recurring items, reached 75 cents—beating analysts’ consensus by 2 cents.
Growth was especially robust in the Cardiovascular segment, which surged 26.8%, while the MedSurg division posted a 15.7% gain. Sub-segments such as Cardiology (+29.3%), Urology (+28.9%), and Peripheral Interventions (+18.3%) also delivered strong performances.
The quarter also marked the successful acquisition of three companies—SoniVie, Bolt Medical, and Intera Oncology—enhancing Boston Scientific’s pipeline and innovation capabilities.
Company Chairman and CEO Mike Mahoney credited the global team’s performance: “This was another strong quarter with excellent top-line growth and margin expansion. Our teams continue to deliver on clinical and commercial excellence while investing in long-term innovation.”
Updated Guidance for 2025
Boston Scientific now expects adjusted EPS for the full year to fall between $2.95 and $2.99, up from its previous forecast of $2.87 to $2.94. Full-year sales growth is now anticipated to be between 18% and 19%, up from 15% to 17%.
Strategic Outlook
During the company’s earnings call, Chief Medical Officer Dr. Ken Stein commented on favorable regulatory developments, particularly a CMS proposal that could broaden Medicare coverage for cardiac ablation procedures—including those performed with Boston Scientific’s Farapulse pulsed field ablation (PFA) system—at ambulatory surgery centers.
The company’s AFib-focused Farapulse PFA system and the Watchman left atrial appendage closure device both received expanded FDA approvals this month, further strengthening Boston Scientific’s arrhythmia treatment portfolio.
Despite some regulatory challenges that led to the discontinuation of its Accurate TAVR system, analysts remain optimistic. Research groups such as Truist, Needham & Co., and BTIG highlighted the company’s ability to outperform high expectations through continued product innovation and strong execution in high-growth segments.
Jul 24,2025
Category：
In The News
Related Information
Videos
Watch the video，Learn more about our products and services.Diagsensor is dedicated to the research and development of ultra-micro sensors for vital signs monitoring
Learn MoreSocial Media
Our Social Media Channels Keep You Informed.
No data